Decreased expression of microRNA‐625 is associated with tumor metastasis and poor prognosis in patients with colorectal cancer. Issue 4 (16th July 2013)

• Record Type: Journal Article
• Authors: Lou, Xiaolou; Qi, Xiaoliang; Zhang, Yong; Long, Houdong; Yang, Jianjun
• Is Part Of: Journal of surgical oncology. Volume 108:Issue 4(2013:Sep. 15)
• Page Start: 230
• Page End: 235
• Publication Date: 2013-07-16
• Subjects: Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.23380
• Languages: English
• ISSNs: 0022-4790

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jso23380-sec-0001" sec-type="section"> <title>Background</title> <p>MicroRNAs (miRNAs) play an essential role in colorectal cancer (CRC) development and progression. Aberrant miR‐625 expression has been reported in several cancers. However, the clinical significance of miR‐625 in human CRC has not been addressed.</p> </sec> <sec id="jso23380-sec-0002" sec-type="section"> <title>Methods</title> <p>miR‐625 expression was determined in 96 pairs of primary CRC and their corresponding adjacent nontumor tissues by quantitative reverse transcriptase‐polymerase chain reaction. Associations of miR‐625 expression with demographic and clinicopathologic features were determined. Additionally, the effects of ectopic expression of miR‐625 on cell migration and invasion were investigated in vitro and in vivo.</p> </sec> <sec id="jso23380-sec-0003" sec-type="section"> <title>Results</title> <p>miR‐625 was significantly downregulated in CRC tissues and cell lines. In addition, the decreased expression of miR‐625 was positively associated with advanced lymph node metastasis (<italic>P</italic> = 0.038), liver metastasis (<italic>P</italic> = 0.031), poor overall survival (<italic>P</italic> = 0.002), and an unfavorable prognosis for CRC patients, as determined through a multivariate analysis (<italic>P</italic> = 0.034). Moreover, functional assays demonstrated that ectopic miR‐625 expression inhibits the invasion and migration of HCT116 CRC cells both in vitro and in vivo.</p> </sec> <sec id="jso23380-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Our results suggest that miR‐625 may serve as an efficient clinical biomarker and a therapeutic tool for the inhibition of metastasis in CRC. <italic>J. Surg. Oncol. 2013 108:230–235</italic>. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>